UPM to Manufacture Products For Amerigen Pharmaceuticals

UPM will commercially manufacture two ANDA products for Amerigen Pharmaceuticals.

UPM, a division of Gregory Pharmaceutical Holdings, has reached an agreement with Amerigen Pharmaceuticals, to commercially manufacture two ANDA products for a 10-year supply term. In addition, the agreement allows for UPM to develop and potentially commercially supply several additional ANDA products for Amerigen over the next few years. UPM acquired a 475,000 ft2 Pfizer manufacturing facility in Bristol, Tennessee in July of 2013, that will supply these products.

Source: UPM

Articles in this issue

over 11 years ago

Article

Using eClinical Systems for Supply-Chain Management

over 11 years ago

Article

Janssen Pharmaceutical Collaborates with Stiching International Dispensary Association

over 11 years ago

Article

FDA and Industry Take Action for a More Secure Drug Supply Chain

over 11 years ago

Article

Packaging Becomes Enabler for Biopharmaceuticals

over 11 years ago

Article

Bristol-Myers Squibb Named First on 2014 Best Corporate Citizens List

over 11 years ago

Article

Azzur Group and BioSPEQ Announce Merger

over 11 years ago

Article

Eli Lilly Launches Second Education Program for Medical Students

over 11 years ago

Article

Global Instability Impacts Brazil's Pharma Market

over 11 years ago

Article

US Biopharma Worries About Losing Lead in Innovation

over 11 years ago

Article

Outsourcing Remains Strong In Traditional Areas

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!